Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 2:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 381 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Albuterol Sulfate Clear all
Completed Phase 3 Interventional Results available

A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent Asthma

NCT01424813
View directory record Official record
Conditions
Asthma
Interventions
Placebo MDPI, Albuterol MDPI
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Costa Mesa, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2015 · Synced Sep 21, 2026, 2:50 PM EDT
Terminated Not applicable Interventional Results available

Repeat Emergency Department Visits Among Patients With Asthma and COPD

NCT02499887
View directory record Official record
Conditions
Asthma, COPD
Interventions
beclamethasone dipropionate, albuterol, Prednisone
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Sep 21, 2026, 2:50 PM EDT
Completed Phase 3 Interventional

Study of Levalbuterol and Racemic Albuterol in Pediatric Subjects With Reactive Airways Disease (RAD)

NCT00685126
View directory record Official record
Conditions
Reactive Airways Disease (RAD)
Interventions
Levalbuterol HCl Inhalation Solution, Albuterol HCl Inhalation Solution
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
Up to 48 Months
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
32
States / cities
Little Rock, Arkansas • Corona, California • Englewood, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Sep 21, 2026, 2:50 PM EDT
Completed Not applicable Interventional

Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate

NCT02649478
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone / Salmeterol, Placebo, Advair Diskus 100/50
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
12 Years and older
Enrollment
1,430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
100
States / cities
Glendale, Arizona • Phoenix, Arizona • Surprise, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 21, 2026, 2:50 PM EDT
Completed Phase 4 Interventional

A Study In Pediatric Subjects With Asthma Using ADVAIR HFA, ADVAIR HFA With Spacer, And ADVAIR DISKUS

NCT00400608
View directory record Official record
Conditions
Asthma
Interventions
ADVAIR HFA, ADVAIR DISKUS
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
4 Years to 11 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
3
States / cities
Huntington Beach, California • Long Beach, California • Medford, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Sep 21, 2026, 2:50 PM EDT
Completed No phase listed Observational

Genetic Influences of Albuterol Response In Children With Bronchiolitis

NCT00570297
View directory record Official record
Conditions
Bronchiolitis
Interventions
Not listed
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
Up to 2 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Sep 21, 2026, 2:50 PM EDT
Completed Phase 3 Interventional

Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma

NCT00073840
View directory record Official record
Conditions
Asthma
Interventions
levalbuterol
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
54
States / cities
Oxford, Alabama • Tucson, Arizona • Corona, California + 49 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Sep 21, 2026, 2:50 PM EDT
Terminated Phase 2 Interventional Results available

Pulmonary Rehab in Chronic Obstructive Pulmonary Disease (COPD): Response to Tyvaso

NCT02178566
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Inhaled Treprostinil
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
40 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Sep 21, 2026, 2:50 PM EDT
Completed Phase 3 Interventional Results available

A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler in Pediatric Asthmatics

NCT02126839
View directory record Official record
Conditions
Asthma
Interventions
Albuterol MDPI, Placebo, ProAir HFA inhaler
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
51
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Alaska + 45 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 21, 2026, 2:50 PM EDT
Completed Phase 4 Interventional Results available

A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Participants13 Years or Older With Asthma

NCT03890666
View directory record Official record
Conditions
Asthma
Interventions
Albuterol eMDPI DS, albuterol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
13 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
29
States / cities
Birmingham, Alabama • Los Angeles, California • Stockton, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Sep 21, 2026, 2:50 PM EDT
Completed Phase 2 Interventional Results available

Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease

NCT02573870
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Batefenterol + Fluticasone Furoate, Placebo, Albuterol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
Phoenix, Arizona • Hollywood, Florida • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Sep 21, 2026, 2:50 PM EDT
Completed Phase 4 Interventional Results available

Effect of Nebulized Bronchodilators on Heart Rate

NCT01151579
View directory record Official record
Conditions
COPD, Sepsis, Shock
Interventions
Levalbuterol, Albuterol
Drug
Lead sponsor
Fahim Khorfan, MD
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Grand Blanc, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 22, 2015 · Synced Sep 21, 2026, 2:50 PM EDT
Completed Phase 3 Interventional Results available

PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction

NCT05555290
View directory record Official record
Conditions
Asthma
Interventions
PT027, PT007
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Columbia, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 21, 2026, 2:50 PM EDT
Terminated Phase 4 Interventional Results available

Inpatient Clinical Trial of NAC

NCT03581084
View directory record Official record
Conditions
Asthma
Interventions
N-acetylcysteine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Sep 21, 2026, 2:50 PM EDT
Completed No phase listed Observational

Eicosanoid Lipids by Airway Cells During Infection With Human Rhinoviruses

NCT01898767
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Sep 21, 2026, 2:50 PM EDT
Recruiting Phase 3 Interventional

Characterization of Bronchodilator Response in Children With Bronchiolitis Using Phenotypic and Genotypic Features

NCT06946264
View directory record Official record
Conditions
Bronchiolitis, Bronchodilator Agents
Interventions
Albuterol Sulfate, 2.5 Mg/3 mL (0.083%) Inhalation Solution, Sodium Chloride 0.9% Inhl 3Ml
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
3 Months to 24 Months
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 21, 2026, 2:50 PM EDT
Completed No phase listed Observational

Replication of the POET-COPD Trial in Healthcare Claims Data

NCT05083429
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Salmeterol, Tiotropium
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 120 Years
Enrollment
8,716 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 21, 2026, 2:50 PM EDT
Terminated Phase 4 Interventional Results available

Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)

NCT03219866
View directory record Official record
Conditions
COPD, COPD Exacerbation
Interventions
Nebulizers, Dry Powder Inhaler, Brovana, Pulmicort, Atrovent, Advair Diskus, Spiriva HandiHaler
Device · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Sep 21, 2026, 2:50 PM EDT
Completed Not applicable Interventional Results available

Phase I Assessment of Hypertonic Saline in Moderate to Severe Asthmatics

NCT03556683
View directory record Official record
Conditions
Moderate to Severe Asthma
Interventions
3% Hypertonic Saline, 7% Hypertonic Saline, Salbutamol
Device · Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Sep 21, 2026, 2:50 PM EDT
Completed Not applicable Interventional Results available

Efficacy of Inhaling Bronchodilator Medications in Chronic Obstructive Pulmonary Disease

NCT01391559
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
arformoterol, salmeterol
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
60 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 6, 2013 · Synced Sep 21, 2026, 2:50 PM EDT
Completed Not applicable Interventional Results available

Sub-Sensitivity to Long-Acting Bronchodilators (LABA)

NCT01117116
View directory record Official record
Conditions
Asthma
Interventions
fluticasone propionate and salmeterol, budesonide and formoterol
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 21, 2026, 2:50 PM EDT
Completed Phase 3 Interventional

A Comparison of the Effects of Tiotropium Inhalation qd and Salmeterol Inhalation Bid on Arterial Blood Gases.

NCT00274534
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium, Salmeterol
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
50 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
2
States / cities
Hines, Illinois • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 4, 2013 · Synced Sep 21, 2026, 2:50 PM EDT
Completed Phase 4 Interventional Results available

The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus

NCT03240575
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium, Olodaterol, Fluticasone propionate, Salmeterol
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
45
States / cities
Jasper, Alabama • Flagstaff, Arizona • Fullerton, California + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2020 · Synced Sep 21, 2026, 2:50 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

NCT04278404
View directory record Official record
Conditions
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions
The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Duke University
Other
Eligibility
0 Years to 20 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
49
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 21, 2026, 2:50 PM EDT